Quantitative changes of melanoma-associated antigens as a biomarker for targeted therapy response

被引：1
|
作者：
Arenberger, Petr [1 ,2 ]
Fialova, Alena [1 ,2 ]
Gkalpakiotis, Spyridon [1 ,2 ]
Pavlikova, Andrea [3 ]
Arenbergerova, Monika [1 ,2 ]
机构：
[1] Charles Univ Prague, Dept Dermatovenereol, Fac Med 3, Srobarova 50, Prague 10034 10, Czech Republic
[2] Fac Hosp Kralovske Vinohrady, Srobarova 50, Prague 10034 10, Czech Republic
[3] Fac Hosp Kralovske Vinohrady, Inst Lab Diagnost, Prague, Czech Republic
来源：
EXPERIMENTAL DERMATOLOGY | 2016年 / 25卷 / 09期
关键词：
biomarker; circulating tumor cell; melanoma; targeted therapy; CIRCULATING TUMOR-CELLS; SURVIVAL; PCR;
D O I：
10.1111/exd.12947
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：727 / 729
页数：3
相关论文
共 50 条
  • [31] Identification of Disease States and Response to Therapy in Humans by Utilizing the Biomarker EGFR for Targeted Molecular Imaging
    Sun, Xilin
    Li, Shaowei
    Shen, Baozhong
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2016, 17 (06) : 534 - 542
  • [32] Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma
    Reijers, Irene L. M.
    Rozeman, Elisa A.
    Wilgenhof, Sofie
    van Thienen, Johannes V.
    Haanen, John B. A. G.
    Blank, Christian U.
    PIGMENT CELL & MELANOMA RESEARCH, 2020, 33 (03) : 498 - 506
  • [33] Incidence of Intracranial Melanoma Progression in the Setting of Positive Extracranial Response to Targeted Therapy and Immunotherapy: An Indication for More Frequent Screening in This Population?
    Gattozzi, Domenico A.
    Rosso, Casey
    Schatmeyer, Bryan A.
    Kabangu, Jean-Luc K.
    Doolittle, Gary C.
    Wang, Fen
    Stepp, Timothy
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (03)
  • [34] Response of BRAFL597Q-mutant Melanoma to Trametinib Targeted Melanoma Therapy beyond BRAFV600-Mutations
    Haase, O.
    Anguen, O.
    Graetz, V.
    Luettmann, N.
    Neumann, A.
    Zillikens, D.
    Terheyden, P.
    HAUTARZT, 2016, 67 (08): : 648 - 651
  • [35] Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st-line BRAF-targeted therapy
    Jones, James
    Lucey, Rebecca
    Corrie, Pippa
    PIGMENT CELL & MELANOMA RESEARCH, 2022, 35 (06) : 595 - 604
  • [36] Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma
    Tompkins, Alexandra G.
    Gray, Zane N.
    Dadey, Rebekah E.
    Zenkin, Serafettin
    Batavani, Nasim
    Newman, Sarah
    Amouzegar, Afsaneh
    Murat, Ak
    Nursima, Ak
    Pak, Taha Yasin
    Peddagangireddy, Vishal
    Mamindla, Priyadarshini
    Amjadzadeh, Mohammadreza
    Behr, Sarah
    Goodman, Amy
    Ploucha, Darcy L.
    Kirkwood, John M.
    Zarour, Hassane M.
    Najjar, Yana G.
    Davar, Diwakar
    Tatsuoka, Curtis
    Colen, Rivka R.
    Luke, Jason John
    Bao, Riyue
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)
  • [37] Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
    Matteo S Carlino
    Vito Vanella
    Christina Girgis
    Diana Giannarelli
    Alex Guminski
    Lucia Festino
    Richard F Kefford
    Alexander M Menzies
    Georgina V Long
    Paolo A Ascierto
    British Journal of Cancer, 2016, 115 : 1280 - 1284
  • [38] Molecular alterations associated with acquired resistance to BRAFV600E targeted therapy in melanoma cells
    Szasz, Istvan
    Koroknai, Viktoria
    Kiss, Timea
    Vizkeleti, Laura
    Adany, Roza
    Balazs, Margit
    MELANOMA RESEARCH, 2019, 29 (04) : 390 - 400
  • [39] Interim analysis of oxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma
    Raja, Chand
    Graham, Peter
    Rizvi, Syed M. Abbas
    Song, Emma
    Goldsmith, Helen
    Thompson, John
    Bosserhoff, Anja
    Morgenstern, Alfred
    Apostolidis, Christos
    Kearsley, John
    Reisfeld, Ralph
    Allen, Barry J.
    CANCER BIOLOGY & THERAPY, 2007, 6 (06) : 846 - 852
  • [40] Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients
    Kasanen, Henna
    Hernberg, Micaela
    Makela, Siru
    Bruck, Oscar
    Juteau, Susanna
    Kohtamaki, Laura
    Ilander, Mette
    Mustjoki, Satu
    Kreutzman, Anna
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (05) : 717 - 730
12345